UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Gottfried E Konecny, MD

Print
Email

Gottfried Konecny, MD

UCLA Physician Gottfried Konecny, MD specializes in Gynecologic Oncology, Hematology & Oncology.
Preferred Name
Gottfried E Konecny
Specialty
Gynecologic Oncology, Hematology & Oncology
Gender
Male
Language Spoken
English, German
Hospital Affiliation
UCLA Medical Center, Santa Monica
State License Number
A124261
Contact
(310) 794-4955
PRACTICE LOCATION

UCLA Hematology/Oncology
100 UCLA Medical Plaza, Suite 550
Los Angeles, CA 90095

EDUCATION
Fellowship
Gynecologic Oncology, Mayo Clinic, 2005 - 2007
Residency
Obstetrics & Gynecology, Klinikum Grosshadern, 1991 - 1996
Internship
Obstetrics & Gynecology, Klinikum Grosshadern, 1989 - 1991
Medical Degree
MD, Ludwig-Maximilians Universitat Muenchen, 1991
CLINICAL INTEREST
Gynecologic Oncology, Ovarian Cancer
AFFILIATION
Department Affiliation
Physician, Hematology / Oncology
MORE INFORMATION
Research Interest
Gottfried E. Konecny is Associate Professor of Medicine at the University of California in Los Angeles and is directing the Translational Oncology Research Program for Gynecologic Oncology in the Department of Medicine at UCLA. It is the primary aim of his basic/clinical translational research in cancer medicine to develop novel targeted treatment strategies for patients diagnosed with breast, endometrial, ovarian and cervical cancer. These efforts are rooted in the understanding that breast, endometrial, ovarian and cervical cancer therapy has begun to shift from a “one size fits all” approach to a personalized approach, in which each patient is treated according to the specific genetic defects in the tumor. His initiatives are directed at using the latest and most effective technologies available to query ovarian cancer tissues, combined with appropriately characterized and molecularly defined preclinical models to identify new alterations and/or understand the role of known pathogenic alterations in relevant genes and molecular pathways. This information is then used to identify, develop and test novel treatment approaches for breast, endometrial, ovarian and cervical cancer. He is the principal investigator of multiple international clinical trials and over the last 3 years has served as the program committee lead in gynecologic oncology for the annual meeting of the American Society of Clinical Oncology.
Publications
  1. Konecny GE, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95(2):142-53, 2003
  2. Pegram MD*, Konecny GE*, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96(10):739-49, 2004 (*Shared first authorship)
  3. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96(15):1141-51, 2004
  4. Konecny GE, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Gilmer T, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 66(3):1630-9, 2006
  5. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner Ch, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Intensive Dose-dense Compared with Conventionally Scheduled Preoperative Chemotherapy for High-risk Primary Breast Cancer. J Clin Oncol 27(18):2938-45, 2009
  6. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 17(6):1591-602, 2011
  7. Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Graus Porta D, Anderson L, Shi MM, Yovine A, Slamon DJ. Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells. Mol Cancer Ther 12(5):632-42, 2013
  8. Pharoah P, Tsai Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Price M, Fridley BL, …, Konecny GE, …., Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro A, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics 45(4):362-70, 2013
  9. Bojesen SE , Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edward SL, Pickett HA,..., Konecny GE,.... Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench, Dunning AM. Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. Nature Genetics 45(4):371-84, 2013
  10. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginter C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong H, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic Potential of the Poly (ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer. Molecular Cancer Ther 12(6):1002-15, 2013
Back to top
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.

Find out how to refer a patient
Dr. Gottfried Konecny,  click here to update your profile.